SCHEMBL16895263

SCHEMBL16895263

O=C1c2ccccc2-c2cnc3ccccc3c21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.46
MAPT P10636 5/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 2/20 0.44
PTK2B Q14289 2/20 0.44
ESR1 P03372 1/20 0.44
MAOA P21397 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
PTPRC P08575 2/20 0.43
CES2 O00748 1/20 0.43
APAF1 O14727 1/20 0.43
TERT O14746 1/20 0.43
PLIN1 O60240 1/20 0.43
TDP2 O95551 1/20 0.43
S1PR4 O95977 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103721 0.93 MEN1 (0.44) DNMT1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL459050 0.85 KMT2A (0.44) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL29641696 0.85 KMT2A (0.44) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL3741119 0.79 TOP1 (0.56) POLBHTTALDH1A1
Calothrixin B SCHEMBL29375353 0.76 CDK4 (0.45) MAPTNPC1RAB9ASMN1; SMN2ESR1
Calothrixin B SCHEMBL5222737 0.76 CDK4 (0.45) MAPTNPC1RAB9ASMN1; SMN2ESR1
SCHEMBL16352244 0.75 MAOA (0.52) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL8874682 0.74 KDM4E (0.42) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL12854093 0.74 ALDH1A1 (0.43) MAPTNPC1RAB9ASMN1; SMN2ESR1
SCHEMBL28057086 0.74 NPC1 (0.59) DNMT1MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2015-07-16 US claimed
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2015-07-16 US disclosed
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF TOP1, TOP2A, TOP2B DNMT1 306/4885MAPT 3314/4885NPC1 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.